169 related articles for article (PubMed ID: 37339341)
21. Leveraging differentiated HIV service delivery to expand tuberculosis preventive treatment: a call to action.
Rabkin M; Howard AA; Ehrenkranz P; Fernandez LG; Preko P; Singh V; Tomlinson HL; El-Sadr WM
Int J Tuberc Lung Dis; 2020 Feb; 24(2):165-169. PubMed ID: 32127099
[TBL] [Abstract][Full Text] [Related]
22. Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe.
Takamiya M; Takarinda K; Balachandra S; Godfrey M; Radin E; Hakim A; Pearson ML; Choto R; Sandy C; Maphosa T; Rogers JH
Int J STD AIDS; 2021 Oct; 32(11):1020-1027. PubMed ID: 33978529
[TBL] [Abstract][Full Text] [Related]
23. Contextualizing and optimizing novel strategies to improve the latent TB continuum of care: Insights from people living with HIV and health care providers in Brazil.
Salles I; Travassos P; Spener-Gomes R; Loch AP; Saraceni V; Lauria L; Cavalcante S; Garcia de Oliveira J; Brito de Souza A; Guimarães Costa A; Sakabe S; Schiavon Nogueira R; Chaisson LH; Cohn S; Jamal LF; Valdez Ramalho Madruga J; Cordeiro-Santos M; Castro B; Portella Ferreira D; Hoffmann CJ; Golub JE; Durovni B; Kerrigan D
PLOS Glob Public Health; 2023; 3(1):e0001251. PubMed ID: 36962892
[TBL] [Abstract][Full Text] [Related]
24. Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial.
Singh P; Moulton LH; Barnes GL; Gupta A; Msandiwa R; Chaisson RE; Martinson NA
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):397-402. PubMed ID: 36000934
[TBL] [Abstract][Full Text] [Related]
25. The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis.
Bastos ML; Melnychuk L; Campbell JR; Oxlade O; Menzies D
PLoS Med; 2021 Sep; 18(9):e1003703. PubMed ID: 34492003
[TBL] [Abstract][Full Text] [Related]
26. Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.
Rahman MT; Hossain F; Banu RS; Islam MS; Alam S; Faisel AJ; Salim H; Cordon O; Suarez P; Hussain H; Roy T
Trop Med Infect Dis; 2023 Dec; 9(1):. PubMed ID: 38276634
[TBL] [Abstract][Full Text] [Related]
27. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
[TBL] [Abstract][Full Text] [Related]
28. Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
Sekaggya-Wiltshire C; Mbabazi I; Nabisere-Arinaitwe R; Banturaki G; Alinaitwe L; Otalo B; Aber F; Nampala J; Owor R; Bayiga J; Laker Agnes Odongpiny E; Castelnuovo B; Mayito J; Sekadde M; Pasipanodya JG; Turyahabwe S; Zawedde-Muyanja S
medRxiv; 2024 Jun; ():. PubMed ID: 38853861
[TBL] [Abstract][Full Text] [Related]
29. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Jarrett RT; van der Heijden Y; Shotwell MS; Chihota V; Marzinke MA; Chaisson RE; Dooley KE; Churchyard GJ
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0129722. PubMed ID: 36622148
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the tuberculosis case-finding and prevention cascade among people living with HIV in Zambia - 2018: a cross-sectional cluster survey.
Melgar M; Shiraishi RW; Tende C; Mwanza S; Mulenga J; Khondowe S; Mwakazanga D; Kapungu K; Tembo M; Nota A; Lungu P; Moore B; Podewils LJ
BMC Public Health; 2021 May; 21(1):859. PubMed ID: 33947361
[TBL] [Abstract][Full Text] [Related]
31. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
32. Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.
Alvarez GG; Sullivan K; Pease C; Van Dyk D; Mallick R; Taljaard M; Grimshaw JM; Amaratunga K; Allen C; Brethour K; Mulpuru S; Pakhale S; Aaron SD; Cameron DW; Alsdurf H; Hui C; Zwerling AA
Int J Infect Dis; 2022 Apr; 117():222-229. PubMed ID: 35121126
[TBL] [Abstract][Full Text] [Related]
33. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
Sung J; Musinguzi A; Kadota JL; Baik Y; Nabunje J; Welishe F; Bishop O; Berger CA; Katahoire A; Nakitende A; Nakimuli J; Akello L; Kasidi JR; Kunihira Tinka L; Kamya MR; Sohn H; Kiwanuka N; Katamba A; Cattamanchi A; Dowdy DW; Semitala FC
Int J Tuberc Lung Dis; 2023 Jun; 27(6):458-464. PubMed ID: 37231600
[No Abstract] [Full Text] [Related]
34. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial.
Semitala FC; Chaisson LH; Dowdy DW; Armstrong DT; Opira B; Aman K; Kamya M; Phillips PPJ; Yoon C
Trials; 2022 May; 23(1):399. PubMed ID: 35550621
[TBL] [Abstract][Full Text] [Related]
35. Tuberculosis preventive treatment uptake among adults living with human immunodeficiency virus: Analysis of Zimbabwe population-based human immunodeficiency virus impact assessment 2020.
Maphosa T; Mirkovic K; Weber RA; Musuka G; Mapingure MP; Ershova J; Laws R; Dobbs T; Coggin W; Sandy C; Apollo T; Mugurungi O; Melchior M; Farahani MS
Int J STD AIDS; 2024 Mar; ():9564624241239186. PubMed ID: 38515336
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
[TBL] [Abstract][Full Text] [Related]
37. Optimizing differentiated treatment models for people living with HIV in urban Zimbabwe: Findings from a mixed methods study.
Rabkin M; Strauss M; Mantell JE; Mapingure M; Masvawure TB; Lamb MR; Zech JM; Musuka G; Chingombe I; Msukwa M; Boccanera R; Gwanzura C; George G; Apollo T
PLoS One; 2020; 15(1):e0228148. PubMed ID: 31990930
[TBL] [Abstract][Full Text] [Related]
38. Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV in PEPFAR-supported countries.
Hirsch-Moverman Y; Hsu A; Abrams EJ; Killam WP; Moore B; Howard AA
PLoS One; 2024; 19(4):e0296993. PubMed ID: 38625930
[TBL] [Abstract][Full Text] [Related]
39. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
[TBL] [Abstract][Full Text] [Related]
40. Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018.
Takarinda KC; Harries AD; Mutasa-Apollo T; Sandy C; Choto RC; Mabaya S; Mbito C; Timire C
BMJ Open; 2020 Apr; 10(4):e034721. PubMed ID: 32265241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
